Alopecia Areata Stocks
Biotechnology firms in this cohort focus on modulating the immune system's response to hair follicles to treat autoimmune-driven hair loss. Revenue models depend on successful clinical transitions from Phase II/III trials toward FDA approval for JAK inhibitors, T-cell modulators, and systemic cytokine therapies.
As of Oct 23, 2026, Alopecia Areata has 7 US-listed companies worth $1.3T combined. The median member moved +4.0% over the past week; MANE led at +27.5% and HCWB trailed at -5.6%.
Companies in Alopecia Areata
- LLY – Eli Lilly and Company, $1.1T
- PFE – Pfizer Inc, $171B
- MANE – Veradermics, Incorporated, $5.8B
- NKTR – Nektar Therapeutics, $1.2B
- QTTB – Q32 Bio Inc, $232M
- IMA – ImageneBio, Inc., $52.4M
- HCWB – HCW Biologics Inc, $2.8M